JP2022516427A5 - - Google Patents

Info

Publication number
JP2022516427A5
JP2022516427A5 JP2021535783A JP2021535783A JP2022516427A5 JP 2022516427 A5 JP2022516427 A5 JP 2022516427A5 JP 2021535783 A JP2021535783 A JP 2021535783A JP 2021535783 A JP2021535783 A JP 2021535783A JP 2022516427 A5 JP2022516427 A5 JP 2022516427A5
Authority
JP
Japan
Prior art keywords
alkyl
heteroaryl
aryl
hydrogen
alkylene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021535783A
Other languages
English (en)
Japanese (ja)
Other versions
JP7590328B2 (ja
JP2022516427A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/068185 external-priority patent/WO2020132658A2/en
Publication of JP2022516427A publication Critical patent/JP2022516427A/ja
Publication of JP2022516427A5 publication Critical patent/JP2022516427A5/ja
Priority to JP2024125601A priority Critical patent/JP2024167209A/ja
Application granted granted Critical
Publication of JP7590328B2 publication Critical patent/JP7590328B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021535783A 2018-12-21 2019-12-20 ツブリシン及びタンパク質-ツブリシンコンジュゲート Active JP7590328B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024125601A JP2024167209A (ja) 2018-12-21 2024-08-01 ツブリシン及びタンパク質-ツブリシンコンジュゲート

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862784325P 2018-12-21 2018-12-21
US62/784,325 2018-12-21
PCT/US2019/068185 WO2020132658A2 (en) 2018-12-21 2019-12-20 Tubulysins and protein-tubulysin conjugates

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024125601A Division JP2024167209A (ja) 2018-12-21 2024-08-01 ツブリシン及びタンパク質-ツブリシンコンジュゲート

Publications (3)

Publication Number Publication Date
JP2022516427A JP2022516427A (ja) 2022-02-28
JP2022516427A5 true JP2022516427A5 (cg-RX-API-DMAC7.html) 2023-01-04
JP7590328B2 JP7590328B2 (ja) 2024-11-26

Family

ID=69185739

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021535783A Active JP7590328B2 (ja) 2018-12-21 2019-12-20 ツブリシン及びタンパク質-ツブリシンコンジュゲート
JP2024125601A Pending JP2024167209A (ja) 2018-12-21 2024-08-01 ツブリシン及びタンパク質-ツブリシンコンジュゲート

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024125601A Pending JP2024167209A (ja) 2018-12-21 2024-08-01 ツブリシン及びタンパク質-ツブリシンコンジュゲート

Country Status (19)

Country Link
US (1) US12144864B2 (cg-RX-API-DMAC7.html)
EP (1) EP3898651A2 (cg-RX-API-DMAC7.html)
JP (2) JP7590328B2 (cg-RX-API-DMAC7.html)
KR (1) KR102911341B1 (cg-RX-API-DMAC7.html)
CN (2) CN113454097B (cg-RX-API-DMAC7.html)
AU (1) AU2019403554B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021011729A2 (cg-RX-API-DMAC7.html)
CA (1) CA3124106A1 (cg-RX-API-DMAC7.html)
CL (2) CL2021001593A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021009129A2 (cg-RX-API-DMAC7.html)
EA (1) EA202191769A1 (cg-RX-API-DMAC7.html)
IL (1) IL283942A (cg-RX-API-DMAC7.html)
MA (2) MA53765B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021007235A (cg-RX-API-DMAC7.html)
MY (1) MY208067A (cg-RX-API-DMAC7.html)
PH (1) PH12021551421A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202106067UA (cg-RX-API-DMAC7.html)
WO (1) WO2020132658A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA202103867B (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020132658A2 (en) 2018-12-21 2020-06-25 Regeneron Pharmaceuticals, Inc. Tubulysins and protein-tubulysin conjugates
MX2022015769A (es) * 2020-06-24 2023-01-19 Regeneron Pharma Tubulisinas y conjugados de proteina-tubulisina.
US11866502B2 (en) 2020-10-22 2024-01-09 Regeneron Pharmaceuticals, Inc. Anti-FGFR2 antibodies and methods of use thereof
MX2023004935A (es) 2020-11-10 2023-07-07 Regeneron Pharma Conjugados de anticuerpos y selenio.
WO2023129518A1 (en) 2021-12-29 2023-07-06 Regeneron Pharmaceuticals, Inc. Tubulysins and protein-tubulysin conjugates
EP4626553A2 (en) 2022-11-30 2025-10-08 Regeneron Pharmaceuticals, Inc. Tlr7 agonists and antibody-drug-conjugates thereof
WO2024235135A1 (zh) * 2023-05-12 2024-11-21 四川科伦博泰生物医药股份有限公司 大环化合物及其制备方法和用途
CN120981249A (zh) * 2023-05-12 2025-11-18 四川科伦博泰生物医药股份有限公司 多环化合物及其制备方法和用途
WO2025117727A1 (en) 2023-11-29 2025-06-05 Regeneron Pharmaceuticals, Inc. Analogs of quinoxaline/quinoline cytotoxins, linker- payloads, protein-drug conjugates, and uses thereof

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US20070258987A1 (en) 2000-11-28 2007-11-08 Seattle Genetics, Inc. Recombinant Anti-Cd30 Antibodies and Uses Thereof
TW200539855A (en) 2004-03-15 2005-12-16 Wyeth Corp Calicheamicin conjugates
NZ551180A (en) 2004-06-01 2009-10-30 Genentech Inc Antibody drug conjugates and methods
US20080305044A1 (en) 2004-11-29 2008-12-11 Seattle Genetics, Inc. Engineered Antibodies and Immunoconjugates
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
WO2008122039A2 (en) 2007-04-02 2008-10-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selenocysteine mediated hybrid antibody molecules
EP2148886B1 (en) * 2007-05-10 2014-02-19 R & D Biopharmaceuticals Gmbh Tubulysine derivatives
US7985557B2 (en) 2007-05-23 2011-07-26 Ventana Medical Systems, Inc. Polymeric carriers for immunohistochemistry and in situ hybridization
US8476451B2 (en) 2007-07-20 2013-07-02 The Regents Of The University Of California Tubulysin D analogues
EP2181101A2 (en) 2007-07-20 2010-05-05 Helmholtz-Zentrum für Infektionsforschung GmbH Tubulysin d analogues
EP2209374B1 (en) * 2007-10-25 2014-12-03 Endocyte, Inc. Tubulysins and processes for preparing
UA108598C2 (xx) 2008-04-30 2015-05-25 Високоефективні кон'югати та гідрофільні зшиваючі агенти (лінкери)
EP2174947A1 (en) 2008-09-25 2010-04-14 Universität des Saarlandes Bioactive pre-tubulysins and use thereof
KR101000067B1 (ko) 2008-12-30 2010-12-10 엘지전자 주식회사 고효율 태양전지용 레이저 소성장치 및 고효율 태양전지 제조방법
IT1394860B1 (it) * 2009-07-22 2012-07-20 Kemotech S R L Composti farmaceutici
US8394922B2 (en) 2009-08-03 2013-03-12 Medarex, Inc. Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
PT2528625E (pt) 2010-04-15 2013-10-17 Spirogen Sarl Pirrolobenzodiazepinas e conjugados das mesmas
US20130244905A1 (en) 2010-07-06 2013-09-19 Ed Grabczyk Reporter for RNA Polymerase II Termination
EP2409983A1 (en) 2010-07-19 2012-01-25 Leibniz-Institut für Pflanzenbiochemie (IPB) Tubulysin analogues
DK2714685T3 (en) 2011-05-27 2017-01-09 Ambrx Inc FORMATIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID BOUND dolastatin
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
CA2850375C (en) 2011-10-14 2019-07-02 Seattle Genetics, Inc. Pyrrolobenzodiazepines and targeted conjugates
JP6166728B2 (ja) 2011-10-14 2017-07-19 メドイミューン・リミテッドMedImmune Limited ピロロベンゾジアゼピンの製造に有用な合成方法及び中間体
AU2012322934B2 (en) 2011-10-14 2016-09-08 Medimmune Limited Pyrrolobenzodiazepines
CA2850373C (en) 2011-10-14 2019-07-16 Seattle Genetics, Inc. Pyrrolobenzodiazepines and targeted conjugates
WO2013068874A1 (en) 2011-11-11 2013-05-16 Pfizer Inc. Antibody-drug conjugates
US20140080175A1 (en) * 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
US9545449B2 (en) 2012-05-11 2017-01-17 Advanced Proteone Therapeutics Inc. Site-specific labeling and targeted delivery of proteins for the treatment of cancer
PL2872157T3 (pl) 2012-07-12 2020-07-13 Hangzhou Dac Biotech Co., Ltd Koniugaty wiążących komórkę cząsteczek ze środkami cytotoksycznymi
HRP20180268T4 (hr) 2012-10-23 2026-03-27 Synaffix B.V. Modificirano antitijelo, konjugat antitijela i postupak za njihovu pripremu
DK2956173T3 (en) 2013-02-14 2017-07-17 Bristol Myers Squibb Co TUBULYSIS RELATIONSHIPS, METHODS OF PRODUCING AND USING THEREOF
US20140249315A1 (en) 2013-03-01 2014-09-04 Endocyte, Inc. Processes for preparing tubulysins
WO2014160360A1 (en) 2013-03-14 2014-10-02 Mersana Therapeutics Inc. Tubulysin compounds and conjugates thereof
GB201309807D0 (en) 2013-05-31 2013-07-17 Pharma Mar Sau Antibody drug conjugates
TWI641620B (zh) * 2013-08-21 2018-11-21 再生元醫藥公司 抗-prlr抗體及其用途
CN105813653B (zh) 2013-12-19 2020-06-26 西雅图基因公司 与目标-药物偶联物并用的亚甲基氨基甲酸酯连接物
WO2015113760A1 (en) * 2014-01-28 2015-08-06 Tube Pharmaceuticals Gmbh Cytotoxic tubulysin compounds for conjugation
CA2945318A1 (en) 2014-04-11 2015-10-15 Medimmune, Llc Tubulysin derivatives
HRP20241124T1 (hr) 2014-09-11 2024-11-22 Seagen Inc. Ciljana isporuka lijekovitih tvari koje sadrže tercijarni amin
CA2962440A1 (en) 2014-09-25 2016-03-31 Endocyte, Inc. Methods of treating cancer with tubulysin conjugates
US10077287B2 (en) * 2014-11-10 2018-09-18 Bristol-Myers Squibb Company Tubulysin analogs and methods of making and use
WO2016089879A1 (en) 2014-12-01 2016-06-09 Endocyte, Inc. Conjugates of garftase inhibitors
CA2969689A1 (en) 2014-12-03 2016-06-09 Genentech, Inc. Quaternary amine compounds and antibody-drug conjugates thereof
KR20170137725A (ko) 2015-02-25 2017-12-13 윌리엄 마쉬 라이스 유니버시티 데스아세톡시투불리신 h 및 이의 유사체
EP3265471A1 (en) 2015-03-01 2018-01-10 Endocyte, Inc. Methods of treating cancer with a psma ligand-tubulysin compound
WO2016168471A1 (en) 2015-04-17 2016-10-20 Endocyte, Inc. Dual disulfide drug conjugates
WO2017031209A1 (en) 2015-08-18 2017-02-23 Endocyte, Inc. Tubulysin analogs and methods
PL3374398T3 (pl) 2015-11-10 2020-08-24 Medimmune, Llc Cząsteczki wiążące swoiste dla ASCT2 i ich zastosowanie
CA3012960A1 (en) 2016-02-01 2017-08-10 Pfizer Inc. Tubulysin analogs and methods for their preparation
HK1259487A1 (zh) 2016-02-04 2019-11-29 Hangzhou Dac Biotech Co. Ltd. 特定的共轭连接子,特定的免疫共轭物,制造和使用这些共轭物的方法
EP3419670A2 (en) 2016-02-26 2019-01-02 Regeneron Pharmaceuticals, Inc. Optimized transglutaminase site-specific antibody conjugation
JP2019518013A (ja) 2016-05-10 2019-06-27 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company 安定性が向上したツブリシン類似体の抗体薬物結合体
KR20240010534A (ko) 2016-08-09 2024-01-23 씨젠 인크. 개선된 물리화학적 특성을 갖는 자기 안정화 링커를 구비한 약물 접합체
KR102520731B1 (ko) 2016-09-23 2023-04-14 리제너론 파아마슈티컬스, 인크. 항-steap2 항체, 항체-약물 컨쥬게이트, 및 steap2 및 cd3에 결합하는 이중특이적 항원-결합 분자, 및 이의 용도
US20180125992A1 (en) * 2016-11-04 2018-05-10 Endocyte, Inc. Drug delivery conjugates of tertiary amine containing drugs
CA3247730A1 (en) 2017-11-07 2025-10-30 Regeneron Pharmaceuticals, Inc. Hydrophilic linkers for antibody drug conjugates
JP7262817B2 (ja) 2017-12-31 2023-04-24 ハンジョウ ディーエーシー バイオテック シーオー.,エルティディ. 分岐連結体を備えたチューブリシン類縁体の共役体
WO2020132658A2 (en) 2018-12-21 2020-06-25 Regeneron Pharmaceuticals, Inc. Tubulysins and protein-tubulysin conjugates
JP2022544442A (ja) 2019-06-24 2022-10-19 ハンジョウ ディーエーシー バイオテック シーオー.,エルティディ. チューブリシン類縁体と細胞結合分子との共役体の製剤
CA3166619A1 (en) * 2020-02-28 2021-09-02 Julian Andreev Bispecific antigen binding molecules that bind her2, and methods of use thereof
MX2022015769A (es) 2020-06-24 2023-01-19 Regeneron Pharma Tubulisinas y conjugados de proteina-tubulisina.
US11866502B2 (en) * 2020-10-22 2024-01-09 Regeneron Pharmaceuticals, Inc. Anti-FGFR2 antibodies and methods of use thereof

Similar Documents

Publication Publication Date Title
AU2020263231B2 (en) Camptothecin derivatives
JP2025160318A5 (cg-RX-API-DMAC7.html)
JP7753372B2 (ja) 重水素化カンプトテシン系誘導体及びその抗体薬物複合体
JP2025160317A5 (cg-RX-API-DMAC7.html)
JP2023182569A (ja) トル様受容体7(TLR7)アゴニストとしての1H-ピラゾロ[4,3-d]ピリミジン化合物ならびにその方法および使用
US10239862B2 (en) Benzazepine compounds, conjugates, and uses thereof
US7008942B2 (en) Cytotoxic agents comprising taxanes and their therapeutic use
JP4398256B2 (ja) 反応性ポリエチレングリコール部分を持つ細胞毒性薬剤、ポリエチレングリコール連結基を含んでなる細胞毒性コンジュゲート、ならびにその製造方法および使用方法
JP2022549510A5 (cg-RX-API-DMAC7.html)
JP2022500413A (ja) Toll様受容体アゴニストの抗体コンジュゲート
KR20080068084A (ko) 씨씨-1065 유사체를 제조하기 위한 방법 및 화합물
US20260022127A1 (en) Hexacyclic topoisomerase inhibitors having cytotoxic activity on cancer cells
EA029901B1 (ru) Соединения для применения в качестве иммуномодуляторов
JP2025510074A5 (cg-RX-API-DMAC7.html)
JP2019537622A (ja) 非線状自壊性リンカーおよびそのコンジュゲート
TW201627286A (zh) 放射性醫藥複合物
JP2020534300A5 (cg-RX-API-DMAC7.html)
ES2323528T3 (es) Inhibidores de la union de la quimiokina sdf-o i-tac al receptor ccxckr2.
JP2005501121A5 (cg-RX-API-DMAC7.html)
CN121971644A (zh) 一类配体药物偶联物及其制备方法和用途
CN120957756A (zh) 稠环化合物及其制备方法和用途
JP2025508328A (ja) 抗体にコンジュゲートした化学的分解誘導物質とその方法
CA3137125C (en) Camptothecin derivatives
RU2019111768A (ru) Противораковые агенты и их получение
RU2026106755A (ru) Конъюгаты, содержащие расщепляемые линкеры